Nanomedicine Tumor Targeting

Abstract

Nanomedicines are extensively explored for cancer therapy. By delivering drug molecules more efficiently to pathological sites and by attenuating their accumulation in healthy organs and tissues, nanomedicine formulations aim to improve the balance between drug efficacy and toxicity. More than 20 cancer nanomedicines are approved for clinical use, and 100′s of formulations are in (pre)clinical development. Over the years, several key pitfalls have been identified as bottlenecks in nanomedicine tumor targeting and translation. These go beyond materials‐ and production‐related issues, and particularly also encompass biological barriers and pathophysiological heterogeneity. In this manuscript, I describe the most important principles, progress and products in nanomedicine tumor targeting, delineate key current problems and challenges, and discuss the most promising future prospects for cancer nanomedicines.This article is protected by copyright. All rights reserved

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

“…82,83 Monitoring these changes can provide real-time information about the disease progression, enabling the development of adaptive and personalized treatment strategies for colorectal cancer patients. 84,85 Despite the tremendous potential of nanomedicine and the protein corona in biomarker discovery, challenges remain in translating these findings into clinical applications. Standardization of nanoparticle characterization, corona analysis, and data interpretation is crucial for ensuring the reproducibility and reliability of the results across different studies.…”

“…Furthermore, the protein corona’s dynamic nature adds an additional layer of complexity to biomarker discovery. As nanoparticles interact with various biological fluids, including blood and interstitial fluid, the composition of the protein corona may evolve over time, reflecting the dynamic changes in the tumor microenvironment. , Monitoring these changes can provide real-time information about the disease progression, enabling the development of adaptive and personalized treatment strategies for colorectal cancer patients. , Despite the tremendous potential of nanomedicine and the protein corona in biomarker discovery, challenges remain in translating these findings into clinical applications. Standardization of nanoparticle characterization, corona analysis, and data interpretation is crucial for ensuring the reproducibility and reliability of the results across different studies.…”

Advanced NIR-II Fluorescence Imaging Technology for Precise Evaluation of Nanomedicine Delivery in Cancer Therapy

“…More importantly, they continue to encounter significant challenges within the body due to tumor heterogeneity and a complex biological environment. These include rapid clearance from the bloodstream, low accumulation at tumor sites, limited penetration into deep tumor tissues, and ineffective cellular internalization [6]. To overcome these hurdles, imaging strategies are crucial for monitoring and guiding the design and optimization of nanomedicines [7].…”

Leveraging machine learning to streamline the development of liposomal drug delivery systems

“…[6][7][8] The size range of 50-200 nm is considered optimal for drug nanocarriers in systemic parenteral administration, balancing tissue and capillary pore size limitations. 6,9,10 Additionally, smaller liposomes (<150 nm) demonstrate enhanced lymphatic uptake and transport, crucial for effective drug delivery. 9,11 Further, larger liposomes might escape clearance and act as longacting depot systems.…”